semaglutide 15 mg FDA approves obesity drug that helped people cut weight 15% – KGET 17 News Co-Pays For GLP-1 Weight Loss

Thus, in a patient treated with GLP-1, weight loss associated with a decrease in SMM/W may reflect a disproportionate muscle loss and point towards a progression to sarcopenic obesity

These criticisms include concerns that wealthy people are using expensive, previously scarce drugs and that influencers are promoting unrealistic expectations of the benefits

Not from the moment you open them

some payors now approve GLP-1s for obesity), though high out-of-pocket costs still limit access a Kaiser Family Foundation survey found ~55% of GLP-1 users struggle to afford their medication ( [1] )

Kidney medicine, 3(2), 282285